News Releases
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
10 19 2017 - Third quarter revenues of $1.93 billion, up 2.4% versus 2016.Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September 30, 2017. "We...
-
10 18 2017 - Cleveland HeartLab to be the base for Quest's first national center of excellence in cardiometabolic disorders, with a focus on services that help patients and physicians nationwide identify hidden risks of heart diseaseQuest Diagnostics (NYSE: DGX) today announced it has formed a definitive agreement to acquire Cleveland HeartLab, a leader in innovative diagnostic services for managing cardiovascular disease,...
-
09 29 2017 Quest acquires service businesses of William W. Backus Hospital and The Hospital of Central ConnecticutQuest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has acquired the outreach lab services operations of two hospitals of Hartford...
-
09 28 2017 Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2017 results on Thursday, October 19, 2017,...
-
09 28 2017 Transaction to expand access to Quest's diagnostic innovations in the New York-New Jersey metropolitan areaQuest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced an agreement under which Quest will acquire the Shiel Medical Laboratory business...
09 28 2017 Analysis of Quest Diagnostics prescription drug monitoring data also found that for more than half of results with concurrent use, one drug had been prescribed by a physician and one had not, suggesting potentially dangerous drug combinations without a physician's oversightMore than 25 percent of patients monitored by lab tests for prescription drug adherence are concurrently taking both opioids and benzodiazepines, according to a new study published online today in...
-
09 27 2017 Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the third quarter of 2017 it expects a reduction in revenues...
-
09 22 2017 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, responded today to the Centers for Medicare and Medicaid Services (CMS) publication of proposed 2018...
-
09 14 2017 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, was named for the thirteenth consecutive year in the North America Dow Jones Sustainability Index...
-
09 07 2017 Quest is first national diagnostic services provider to use novel LDL-cholesterol calculation that improves accuracy of heart disease screening and helps personalize treatment with lipid-lowering medications such as PCSK9 inhibitors and statinsQuest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that all of the company's cholesterol test services that involve estimates of...